Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18–70 Years; A Randomized, Double-Blind Clinical Trial
Authors:
- 11 October 2023
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (12) , 3012-3021
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging studyThe Lancet Infectious Diseases, 2021
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccineVaccine, 2021
- Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidatesScientific Reports, 2021
- The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 PandemicFrontiers in Immunology, 2021
- Adaptive immunity to SARS-CoV-2 and COVID-19Cell, 2021
- Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trialEmerging Microbes & Infections, 2021
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineNew England Journal of Medicine, 2020
- Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy AdultsClinical Infectious Diseases, 2020
- A systematic review of SARS-CoV-2 vaccine candidatesSignal Transduction and Targeted Therapy, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020